## Review setup
- **Input scope** Abstract only
- **Assessment boundary** Claims and evidence presented in the abstract, with no access to full methods, figures, tables, or supplementary data
- **Shared manuscript claim summary** The authors report synthesis and characterization of a novel Pd(II) complex, [Pd(dach)(SSA)], with DFT-based stability and reactivity analysis, cytotoxicity against K562 cells, lipophilicity measurement, and multi-technique binding studies with CT-DNA and BSA, concluding non-intercalative DNA binding, static quenching, protein secondary structure alteration, and stable complex formation supported by docking and molecular dynamics simulations.
- **Visible evidence base** Abstract text only; no experimental procedures, spectral data, statistical analyses, or simulation parameters are provided
- **Missing materials affecting confidence** Full manuscript, methods section, all figures and tables, raw spectroscopic data, DFT output details, docking scores, MD trajectory analyses, cytotoxicity dose-response curves, and statistical treatment

## Reviewer
- **Overall assessment** The abstract presents a broad and ambitious study combining synthesis, computational chemistry, biophysical binding assays, and cytotoxicity evaluation. However, the compressed format leaves many critical claims undersupported or unverifiable. The central conclusions regarding binding affinity, quenching mechanism, and structural effects rest on data that cannot be assessed from the abstract alone. The work is potentially of interest to the bioinorganic and anticancer drug development communities, but the evidence base provided is insufficient to establish the case.
- **Who would be interested in the results, and why** Researchers in bioinorganic chemistry, anticancer metallodrug design, and biophysical chemistry would find the comparative binding study of a Pd(II) complex with DNA and protein relevant. The combination of experimental and computational approaches may appeal to those studying structure-activity relationships of metal-based therapeutics.
- **Major strengths** The study integrates multiple complementary techniques, including spectroscopy, viscosity, docking, and MD simulation, which is commendable for characterizing metal-biomolecule interactions. The comparative analysis of DNA versus BSA binding provides a useful framework for assessing selectivity. The inclusion of DFT calculations adds a theoretical dimension that strengthens the physicochemical characterization.
- **Major Concerns**  
  - R1-M1  
  - R1-M2  
  - R1-M3  
  - R1-M4  
  - R1-M5
- **Minor Comments**  
  - R1-m1  
  - R1-m2  
  - R1-m3  
  - R1-m4  
  - R1-m5
- **Technical failings that need to be addressed before the case is established** R1-M1, R1-M2, R1-M3, R1-M4, R1-M5
- **Assessment against Nature-style criteria** Originality is moderate; the use of Pd(II) complexes with dach and sulfosalicylate ligands is not unprecedented, and the binding study follows established protocols. Scientific importance is limited by the lack of mechanistic novelty and the absence of in vivo or advanced cellular data. Interdisciplinary readership is plausible given the combination of chemistry, biology, and computation, but the abstract does not clearly articulate broader implications. Technical soundness cannot be fully evaluated from the abstract; several claims lack quantitative or statistical support. Readability for nonspecialists is acceptable but hindered by undefined acronyms and dense presentation of results without context.
- **Recommendation posture** Currently not established from the provided evidence. The abstract alone does not provide sufficient detail to validate the core claims. A full manuscript with complete methods, data, and statistical analyses would be required to assess whether the conclusions are justified.

### Major Concerns

- **Concern ID** R1-M1  
- **Severity** Major  
- **Blocking** Yes  
- **Axis** Evidence sufficiency  
- **Claim pointer** The abstract claims that DFT calculations (geometry optimization, MEP, HOMO-LUMO, NBO) demonstrate the palladium compound is stable and that MEP shows potential interaction sites.  
- **Evidence pointer** Abstract text; location not provided  
- **Concern** The abstract states that NBO and HOMO-LUMO analysis "exhibited that the palladium compound is stable," but no numerical data, such as HOMO-LUMO energy gaps, NBO charges, or stabilization energies, are provided. Stability is a quantitative concept that cannot be asserted without specific values or comparative benchmarks.  
- **Why it matters** The DFT-based stability claim is foundational to the physicochemical characterization of the complex. Without quantitative output, readers cannot verify the conclusion or compare it with other complexes.  
- **Resolution test** Provide the HOMO-LUMO gap, NBO charge distributions, and any relevant stabilization energies, along with a clear interpretation of how these values support stability.

- **Concern ID** R1-M2  
- **Severity** Major  
- **Blocking** Yes  
- **Axis** Evidence sufficiency  
- **Claim pointer** The abstract claims that the Pd(II) complex shows "proper activity" against K562 cells compared to cisplatin, based on MTT assay.  
- **Evidence pointer** Abstract text; location not provided  
- **Concern** No IC50 values, dose-response curves, or statistical comparisons with cisplatin are reported. The term "proper activity" is vague and does not allow assessment of potency or significance.  
- **Why it matters** Cytotoxicity is a key translational claim. Without quantitative data and statistical analysis, the comparison to cisplatin is unsubstantiated.  
- **Resolution test** Report IC50 values with standard deviations, number of replicates, and statistical tests comparing the complex to cisplatin under identical conditions.

- **Concern ID** R1-M3  
- **Severity** Major  
- **Blocking** Yes  
- **Axis** Evidence sufficiency  
- **Claim pointer** The abstract claims that CD and UV-Vis spectroscopy demonstrated that the compound "refolded the protein via increasing the alpha helix percentage."  
- **Evidence pointer** Abstract text; location not provided  
- **Concern** The claim of protein refolding and increased alpha helix percentage is presented without any quantitative data, such as percent helicity values, CD spectra at specific wavelengths, or comparison to native BSA. Refolding is a strong mechanistic statement that requires structural evidence.  
- **Why it matters** Protein conformational changes are central to understanding the compound's interaction with BSA. Without quantitative CD data, the claim is not verifiable.  
- **Resolution test** Provide CD spectra with molar ellipticity values, calculated secondary structure percentages, and a clear description of how refolding was determined.

- **Concern ID** R1-M4  
- **Severity** Major  
- **Blocking** Yes  
- **Axis** Evidence sufficiency  
- **Claim pointer** The abstract claims that UV-Vis studies indicated non-intercalative interaction between the Pd(II) complex and DNA, and reports K(app) values of 7.43 x 10^4 M^-1 for CT-DNA and 5.17 x 10^3 M^-1 for BSA, and L(1/2) values of 5 microM and 5.7 microM, respectively.  
- **Evidence pointer** Abstract text; location not provided  
- **Concern** The binding constants and midpoint transition values are reported without error margins, number of experiments, or the method of calculation. The conclusion of non-intercalative binding is not supported by any specific spectral evidence, such as hypochromism or bathochromic shifts.  
- **Why it matters** Binding affinity and mode are central claims. Without statistical treatment and raw spectral data, the values and the mechanistic conclusion cannot be evaluated.  
- **Resolution test** Provide binding constants with standard errors, replicate numbers, and representative UV-Vis spectra showing spectral changes. Justify the non-intercalative assignment with reference to established criteria.

- **Concern ID** R1-M5  
- **Severity** Major  
- **Blocking** Yes  
- **Axis** Evidence sufficiency  
- **Claim pointer** The abstract claims that molecular dynamics simulation validated the stability of the metal compound-DNA/-BSA complexes in water over time.  
- **Evidence pointer** Abstract text; location not provided  
- **Concern** No simulation parameters, time scales, RMSD/RMSF values, or convergence criteria are provided. The claim of "stability" is qualitative and cannot be assessed without trajectory analysis.  
- **Why it matters** MD simulation is used to support the biological relevance of the binding. Without quantitative metrics, the claim of stability is unverifiable.  
- **Resolution test** Provide simulation duration, force field, water model, RMSD and RMSF plots, and a clear definition of stability based on these metrics.

### Minor Comments

- **Concern ID** R1-m1  
- **Severity** Minor  
- **Axis** Clarity  
- **Affected element** Title and abstract terminology  
- **Evidence pointer** Abstract text  
- **Issue** The title uses "Bio-Macromulecules," which appears to be a typographical error for "Bio-Macromolecules."  
- **Required correction** Correct the spelling in the title.

- **Concern ID** R1-m2  
- **Severity** Minor  
- **Axis** Completeness  
- **Affected element** Lipophilicity claim  
- **Evidence pointer** Abstract text  
- **Issue** The abstract states that partition coefficient measurement follows the order cisplatin < Pd(II) complex, but no numerical values or method (e.g., shake-flask, HPLC) are provided.  
- **Required correction** Report the measured partition coefficient values and the method used.

- **Concern ID** R1-m3  
- **Severity** Minor  
- **Axis** Clarity  
- **Affected element** Thermodynamic parameters  
- **Evidence pointer** Abstract text  
- **Issue** The abstract reports DeltaS degrees < 0 and DeltaH degrees < 0 but does not specify the temperature at which these were determined or the method of calculation.  
- **Required correction** Specify the experimental temperature and the van't Hoff or other analysis used.

- **Concern ID** R1-m4  
- **Severity** Minor  
- **Axis** Completeness  
- **Affected element** Gel electrophoresis claim  
- **Evidence pointer** Abstract text  
- **Issue** DNA gel electrophoresis is listed as a method, but no results or conclusions from this experiment are described.  
- **Required correction** Either report the gel electrophoresis results or remove the mention from the abstract.

- **Concern ID** R1-m5  
- **Severity** Minor  
- **Axis** Clarity  
- **Affected element** Docking site claim  
- **Evidence pointer** Abstract text  
- **Issue** The abstract states that molecular docking indicated the compound fits into the groove of DNA and site I of BSA, but no docking scores or binding energies are provided.  
- **Required correction** Report docking scores or binding free energies to support the binding site claims.

## Risk / unsupported claims
- The DFT-based stability claim is unsupported without quantitative data.
- The cytotoxicity comparison to cisplatin is unsupported without IC50 values and statistics.
- The protein refolding and alpha helix increase claim is unsupported without CD data.
- The binding constants and non-intercalative mode are unsupported without error margins and spectral evidence.
- The MD simulation stability claim is unsupported without trajectory metrics.
- The lipophilicity order is unsupported without numerical values.
- The thermodynamic parameter interpretation is unsupported without temperature and calculation details.
- The gel electrophoresis and docking site claims are unverifiable without results or scores.